Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.

BACKGROUND This study investigates response and prognosis after neo-adjuvant chemoradiation (CTx/RTx) in patients with advanced esophageal carcinoma, according to histological type. PATIENTS AND METHODS Patients with uT3 carcinoma of the esophagus treated with curative-intention esophagectomy from 1997 until 2006 were included in this retrospective analysis. Patients receiving preoperative CTx/RTx (5-fluorouracil, cisplatin, 36 Gy) were compared with those with primary surgery for pT3 tumors. Therapy response after CTx/RTx was evaluated using 'Cologne Regression Grade' (minor response: >or=10% vital residual tumor cells (VRTCs), major response: <10% VRTC or pathologic complete response). Prognosis was evaluated for adenocarcinoma (AC) and squamous cell carcinoma (SCC). RESULTS Of 297 patients, 52% were SCC and 48% AC. In all, 192 patients underwent CTx/RTx, 100 (65%) SCC and 92 (64%) AC (nonsignificant). In SCC group 51% and in AC group 29% achieved major response (P < 0.01). Patients with major response had a 2-year survival rate (2y-SR) of 78% versus those with minor response or without CTx/RTx, with a 2y-SR of 45% (P = 0.001). Examining patients with major response exclusively, the prognosis of AC (2y-SR 85%) is better than that of SCC (2y-SR 54%) (P < 0.01). CONCLUSION This retrospective study concludes that in esophageal tumors, response to and prognosis after neo-adjuvant CTx/RTx vary according to histology.

[1]  T. Demeester,et al.  Vagal-sparing esophagectomy. , 2008, Advances in surgery.

[2]  J. Hagen,et al.  Vagal-Sparing Esophagectomy: The Ideal Operation for Intramucosal Adenocarcinoma and Barrett with High-Grade Dysplasia , 2007, Annals of surgery.

[3]  J. Ajani,et al.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Mariette,et al.  Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. , 2007, The Lancet. Oncology.

[5]  Charles R. Thomas,et al.  Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer. , 2007, American journal of surgery.

[6]  A. Esterman,et al.  An Evaluation of Prognostic Factors and Tumor Staging of Resected Carcinoma of the Esophagus , 2007, Annals of surgery.

[7]  Val Gebski,et al.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.

[8]  C. Gutschow,et al.  Laparoscopic Ischemic Conditioning of the Stomach for Esophageal Replacement , 2007, Annals of surgery.

[9]  J. Izbicki,et al.  Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer , 2007, Annals of Surgical Oncology.

[10]  A. Krasinskas,et al.  Excellent Interobserver Agreement on Grading the Extent of Residual Carcinoma After Preoperative Chemoradiation in Esophageal and Esophagogastric Junction Carcinoma: A Reliable Predictor for Patient Outcome , 2007, The American journal of surgical pathology.

[11]  J. Lagergren,et al.  Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population-based Study , 2006, World Journal of Surgery.

[12]  J. Reynolds,et al.  Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. , 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[13]  A. Hölscher,et al.  Preoperative risk analysis—a reliable predictor of postoperative outcome after transthoracic esophagectomy? , 2006, Langenbeck's Archives of Surgery.

[14]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[15]  S. Bentzen,et al.  Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  J. Ajani,et al.  Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy , 2006, Cancer.

[17]  S. Baldus,et al.  Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification , 2005, Annals of surgery.

[18]  S. Motoyama,et al.  A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. , 2005, Journal of the American College of Surgeons.

[19]  J. Birkmeyer,et al.  Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. , 2005, Surgery.

[20]  R. Müller,et al.  Regression von Ösophaguskarzinomen nach neoadjuvanter Radiochemotherapie , 2004, Der Pathologe.

[21]  R. Müller,et al.  [Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation]. , 2004, Der Pathologe.

[22]  A. Venturi,et al.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis , 2004, Gut.

[23]  R. Fietkau.  Definitive and Neoadjuvant Radiochemotherapy of Squamous Cell Carcinoma of the Oesophagus , 2004, Oncology Research and Treatment.

[24]  A. Nakagawa,et al.  Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[26]  E. Bollschweiler.  Benefits and limitations of Kaplan–Meier calculations of survival chance in cancer surgery , 2003, Langenbeck's Archives of Surgery.

[27]  A. Hölscher,et al.  [How safe is high intrathoracic esophagogastrostomy?]. , 2003, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[28]  W. Schröder,et al.  Wie sicher ist die hoch intrathorakale Ösophagogastrostomie? , 2003, Der Chirurg.

[29]  J. Ajani,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction , 2002 .

[30]  Douglas G Altman,et al.  Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.

[31]  J. Urschel,et al.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. , 2002, American journal of surgery.

[32]  S. Post,et al.  Neoadjuvant Radio-Chemotherapy of Adenocarcinoma of the Oesophagogastric Junction , 2001, Oncology Research and Treatment.

[33]  J. Siewert,et al.  Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus , 2000, The British journal of surgery.

[34]  F. Shanahan,et al.  Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. , 1999, Gastroenterology.

[35]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[36]  A. Hölscher,et al.  Early adenocarcinoma in Barrett's oesophagus , 1997, The British journal of surgery.

[37]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[38]  H. Höfler,et al.  Prognostic factors of resected adenocarcinoma of the esophagus. , 1995, Surgery.

[39]  A. Hölscher,et al.  Prognosis of early esophageal cancer. Comparison between adeno‐and squamous cell carcinoma , 1995, Cancer.

[40]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[41]  A. Cassoni.  Tnm Classification of Malignant Tumours , 1987 .

[42]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[43]  K. Schulmann,et al.  Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment , 2005, Journal of Cancer Research and Clinical Oncology.

[44]  A. Livingstone,et al.  Neoadjuvant Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal Junction: A Meta-Analysis of Randomized Clinical Trials , 2003, Annals of Surgical Oncology.

[45]  J. Urschel,et al.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. , 2002, American journal of surgery.

[46]  B. Cesana,et al.  Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. , 2001, Surgery.

[47]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[48]  Y. Shimosato,et al.  Histological Evaluation of Effects of Radiotherapy and Chemotherapy for carcinomas , 1971 .